Brief Report: No Excess Risks in Offspring With Paternal Preconception Exposure to Disease‐Modifying Antirheumatic Drugs

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|67|1|296-301

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.67, Iss.1, 2015-01, pp. : 296-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patients' Considerations in the Decision‐Making Process of Initiating Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 7, 2015-07 ,pp. : 956-964

John Wiley & Sons Inc

Access to resources Recommend Favorite

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1671-1678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 20, Iss. 11, 2017-11 ,pp. : 1795-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: Inflammation, Disease‐Modifying Antirheumatic Drugs, Lipids, and Cardiovascular Risk in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 2, 2015-02 ,pp. : 327-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use and Spending for Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 9, 2015-09 ,pp. : 1210-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite